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phism genotype distribution and allele frequency were different between pts and controls 
(chi(2)= 36.26, p<O.OOOl and chi(2)= 33.57, p<O.OOOl, respectively). At unlvariate analy- 
sis ACE DD genotype was associated with the risk of AF (OR DD/ID+ll=2.64, p-zO.0001). 
The analysis of endothelial NO synthase (eNOS) T-766-C G694T and 4e/4b polymor- 
phisms did not show a significant difference in the genotype distribution and allele fre- 
quency between pts and controls but a slight difference in 4ei4b eNOS polymorphism 
was observed. These data confirm that ACE I/D polymorphism is involved in AF; the pa?.- 
sible role of altered NO synthesis requires to be furtherly investigated. 
11211 MP-163 Radiation Exposure on Paroxysmal Atrial Fibrillation 
Catheter Ablation 
Mauricio Scanavacca, Nelson Samesima, Jose Caballero, Raul Sartini, Silvano 
Diangelo, Fernando Piza, Carina Hardy, Eduardo Sosa, Heart Institute (Incor), University 
of SBo Paula Medical School, SLo Paula, Brazil 
Background: The pulmonary veins disconnection (PVD) with radiofrequency (RF) cathe- 
ter ablation is a new developing technique to treat paroxysmal atrial fibrillation (PAF). It is 
a long procedure (3 to 4 hours) and a second performance is not uncommon. Objective: 
To quantify the radiation exposure for patient and operator during PAF RF catheter abla- 
tion. Methods: Radiation exposure using a pulsed fluoroscopy (7 frames/s) was analyzed 
in nine consecutive patients submitted to PVD procedure (7 male; mean age: 53+/-13~; 
3+/-l PVDipatient). Four thermoluminescent dosimeters (TLDs) were used to measure 
the absorbed racfiatlon in each patient: two on the anterior chest and two on the back 
(right and left). The operator’s exposition was evaluated by two TLDs, one under the 
plumber shield (abdomen) and one next to the face. Another TLD was left 7 feet away 
from the X ray source to evaluate the staff radiation exposure. Results: The X ray total 
dose and the mean dose per procedure for the patients, operator and staff are shown in 
table 1. The maximum permissible annual dose exposure according to the Nuclear 
Energy National Commission is SOOmSv. The mean procedure time was 233+1-30min 
and the mean X ray time was 13+/-2min. Conclusion: The amount of absorbed radiation 
in PAF RF catheter ablation is quite acceptable to the operator and staff but it is high to 
the patient. If a second PAF RF ablation procedure is necessary before one year, the 
patient might be excessively exposured to radiation. 
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1211 MP-166 Angiotensin Converting Enzyme Inhibitors Do Not 
Prevent Supraventricular Tachyarrhythmias: Evidence 
From the SOLVD Trial 
Keith A. Kyker, Omer L. Shedd, Jamie B. Conti, Mario D. Gonzalez, Anne B. Curtis, 
University of Florida, Gainesville, FL 
Background: Recent data has suggested that the incidence of atrial arrhythmias may be 
reduced by treatment with ACE inhibitors, possibly by prevention of atrial electrical 
remodeling. 
Methods: We reviewed data from the Studies of Left Ventricular Dysfunction (SOLVD) 
Trial, a prospective, randomized, multicenter clinical trial in which patients with left ven- 
tricular dysfunction and Class II-IV heart failure were treated either with enalapril or pla- 
cebo, with the primary endpoint being total mortality. During follow-up, the occurrence of 
any supraventricular tachycardia (S/T), mainly atrial fibrillation I” a heart failure popula- 
tion, was recorded es: (1) a diagnosis causing hospital admission, or (2) SVT requiring 
treatment or cardioversion. A total of 1,130 patients with specific documentation of the 
presence or absence of SVT were included in this review. 
Results: In these 1,130 patients, 2.9% (lLV624) of the enalapril treatment group versus 
3.8% (19/506) of the placebo group had SVT es the diagnosis for admission (p=O.50). As 
a secondary diagnosis, the incidence of SVT was 4.7% (29/624) for the enalapril group 
compared with 3.2% (lLY506) for the placebo group (~~0.2). Combining the above 
results, the total incidence of SVT was 6.9% for the enalapril group versu?. 6.7% for the 
placebo group (p=l .O). 
SVT 
Table I: X Ray Dose Dismbution Treatment NO Yes Total 
X ray total dose (m.Sv) 2662 0,4 2,4 0,3 
Mean X ray dose/procedure (mSv) 298 0,04 0,26 0,03 
Enalapril 
Patients operator Staff 
Placebo 
Abdomen Face 
581 (93.1%) 
472 (93.3%) 
43 (6.9%) 624 
34 (6.7%) 506 
Conclusion: In a large population of patients with left ventricular dysfunction and con- 
gestive heart failure, treatment with enalapril did not significantly affect the incidence of 
SVT compared to placebo. 
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Initiation and Recurrence of Atrial Fibrillation 
Nassir F. Marrouche, Walid Saliba. Alejandro Perez-Lugones, Eduardo Saad, Mandeep 
Bhargava, Oussama Wazni. Mustaphasahim Shaaraoui, Ahmad Abdul-Karim. Robert 
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Background: Electrical ostial isolation of pulmonary veins (PVs) has been proven to be 
effective in curing patients with atrial fibrillation (AF). Whether is important to Isolate the 
right inferior pulmonary vein remains unclear. In this study we report the role of the right 
lower PV in initiation and recurrence AF. Methods and Results: Three hundred and 
eighty one patients presented for circular mapping guided PVs isolation (290 men; mean 
age 54+11 years) for treatment of symptomatic AF. Arrhythmogenic PV (APV) initiating 
atrial premature contractions causing AF was defined in the first 211 patients. Fifty-two 
(15%) out of 354 arrhyihmogenic PVs were RIPVs. Out of 361 patients 68 (18%) experi- 
enced recurrence of AF after a mean follow-up of 31Oi105 days. Twenty two out of 68 
patients underwent a 2ti PV isolation procedure. In 22% of these patients (5122) the 
RIPV was defined to be the APV causing AF at follow-up. Conclusion: From our preliml- 
nary experience, the right lower PV is responsible for initiation of AF in at least 15% of 
patients presenting with AF. Isolation of the RIPV should always be considered in 
patients with AF in order to maximize long-term cure. 
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1211 MP-167 Supraventricular Arrhythmias in the U.S. Population: A 
Rapidly Accelerating Epidemic in the Elderly 
D. Douqlas Miller, Joseph S. Alpert, Saint Louis University, St. Louis, MO 
Background: The 2002 ACC/AHAJESC pracbce guidelines task force on supraventricu- 
lar arrhythmias(SVA), excluding atrial fibrillation (A Fib), determined that incidence. prev- 
alence and hospitalization data for SVA were incomplete or lacking. 
Methods: A prospective review of 2 large U.S. hospital databases(l998 Medicare Pro- 
vider Analysis & Review/MEDPAR and Health Care Financing Administration dis- 
charges), and the 1999 Department of Health & Human Services national discharge 
survey for ICD-9 CM codes 427.~~ forms the basis for SVA hospitalization and discharge 
statistics I” the table. Prevalence was based on the 1996 Centers for Disease Control 
Vital and Health Statistics current estimates from the National Health Interview Survey. 
ReeultS: SVA IS an infrequent primary hospital diagnosis compared to A Fib, but it has 
comparable case fatelity(=l% vs 1.7%). average length of stay(LOS=4.2 vs 4.7 day?.) 
and average Medicare relmbursement(=$3,802 vs $3,559). Overall prevalence for parox- 
ysmal SVA &Jor unspecified rapid heart action in the US. population was 4.3 mil- 
lion(8.7%). The SVA risk ratio(RR) for pts. aged >65 yrs. versus ~45 yrs. was 8.2(male 
RR = 6.2; female RR ~10.7). 
Conclusion: The expert ACCIAHAIESC committee on SVA concludes that paroxysmal 
SVA (excluding A Fib) is a relatively prevalent condltlon, currently affecbng ~-30% of the 
elderly US population. The rapid aging of the U.S. population will likely contrIbute to 
increasing prevalence and medical costs for SVA in the coming decades. 
1211 MP-I 65 High Prevalence of ACE DD and Genotype in Patients 
Year Hospital % of Total &Se Average % Aged 
With Atrial Fibrillation 
Population Discharges Fatality Rate LOS (days) ~65 yrs 
1998 Medicare 3.8% 1.0% 4.2 99% 
Antonio Michelucci, Francesca Gensini, Luigi Padeletti, Cinzia Fatlni, Elena Sticchi, 
Mirella COPPO, Andrea Colella. Paolo Pieraanoli, Nicola Musilli. Maria C. Porciani, 
1999 Non-Federal 1 .I % 0.96% 3.6 58% 
Rosanna Abbate, Daniela Poll, G~anFranco Gensinl, University of Florence, Florence, 
Italy 
Increased expression of angiotensin converting enzyme (ACE) in atrlal tissue of patients 
with atrial fibrillation (AF) suggested the involvement of Renin Angiotensin System in AF. 
Prevws results from our group suggested a different distribution of ACE polymorphism 
in AF. In a larger sample (208 pts with persistent AF and 210 controls) ACE l/D polymor- 
